 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
3 News |  |
- | T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Journal: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002. (Pubmed Central) - Dec 4, 2023
No abstract available
- || T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
My problem is it requires Instagram and my Instagram is connected to my Facebook which is my wallet name which I don't guard closely (there are a fair number of people who called me Val before FB changed that) but I don't use on Twitter. Or can I make one without an Instagram? (Twitter) - Jul 8, 2023
- || T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
He’s a likable guy who gets hot from 3 and can’t guard a statue. (Twitter) - Jul 1, 2023
- | T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (clinicaltrials.gov) - Jan 25, 2023
P3, N=12, Terminated, Sponsor: Xenikos
No abstract available N=246 --> 12 | Trial completion date: Jun 2026 --> Jan 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Nov 2022; The study met the protocol defined stopping boundary for Day 60 mortality when comparing mortality between the T-Guard and ruxolitinib arms
- ||||| T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Trial completion date, Trial initiation date, Trial primary completion date: A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (clinicaltrials.gov) - Mar 21, 2022
P3, N=246, Recruiting, Sponsor: Xenikos
N=246 --> 12 | Trial completion date: Jun 2026 --> Jan 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Nov 2022; The study met the protocol defined stopping boundary for Day 60 mortality when comparing mortality between the T-Guard and ruxolitinib arms Trial completion date: Jan 2026 --> Apr 2026 | Initiation date: Dec 2021 --> Mar 2022 | Trial primary completion date: Jan 2025 --> Apr 2025
- || T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Those of us who are disabled know there are those who will. And many more who just won't try as hard. You may not. If you give it a few minutes, you can think of physicians who might. And that's just the ones who don't guard their biases in front of those who may not share them. (Twitter) - Jan 18, 2022
- |||||| T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Enrollment open: A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (clinicaltrials.gov) - Dec 13, 2021
P3, N=246, Recruiting, Sponsor: Xenikos
Trial completion date: Jan 2026 --> Apr 2026 | Initiation date: Dec 2021 --> Mar 2022 | Trial primary completion date: Jan 2025 --> Apr 2025 Not yet recruiting --> Recruiting
- ||||| T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Trial initiation date: A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (clinicaltrials.gov) - Dec 2, 2021
P3, N=246, Not yet recruiting, Sponsor: Xenikos
Not yet recruiting --> Recruiting Initiation date: Sep 2021 --> Dec 2021
- |||| T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos, Jakafi oral (ruxolitinib) / Novartis, Incyte
Clinical: Story of how a toxicities of @BMTCTN 1802 informed design of @bmtctn 2002 randomized study of #jakafi vs. T-guard in grade 3,4 aGVHD refractory #GvHD #bmtsm Meyer and Levine et al. https://t.co/wMXkVek2xE (Twitter) - Nov 24, 2021
- |||| T-Guard (Combination of SPV-T3a-RTA and WT1-RTA) / Xenikos, Jakafi oral (ruxolitinib) / Novartis, Incyte
Clinical: At the time of ruxolitinib initiation, 51 (80%) patients had Grade III/IV SR-aGVHD These high risk patients are group of unmet need and focus of @BMTCTN trial 2002 randomizing grade 3-4 patients to Rux vs. T-Guard led by Drs. Levine, Meyers & Socie (Twitter) - Jul 13, 2021
- |||||||||| T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
New P3 trial: A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (clinicaltrials.gov) - Jun 22, 2021
P3, N=246, Not yet recruiting, Sponsor: Xenikos
- || T-Guard (Combination of SPV-T3a-RTA and WT1-RTA) / Xenikos B.V.
Not universally true. Some don't guard, some species guard, some can be induced to guard if a threat is perceived. (Twitter) - Sep 27, 2020
- | T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) (clinicaltrials.gov) - Aug 27, 2020
P3, N=3, Terminated, Sponsor: Xenikos
Initiation date: Sep 2021 --> Dec 2021 N=47 --> 3 | Trial completion date: Sep 2021 --> Feb 2020 | Suspended --> Terminated | Trial primary completion date: Nov 2020 --> Feb 2020; Initiated a new randomized trial per discussion with FDA
- ||| T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Trial suspension: T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) (clinicaltrials.gov) - Mar 23, 2020
P3, N=47, Suspended, Sponsor: Xenikos
N=47 --> 3 | Trial completion date: Sep 2021 --> Feb 2020 | Suspended --> Terminated | Trial primary completion date: Nov 2020 --> Feb 2020; Initiated a new randomized trial per discussion with FDA Recruiting --> Suspended
- || T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Enrollment open: T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) (clinicaltrials.gov) - Nov 29, 2019
P3, N=47, Recruiting, Sponsor: Xenikos
Recruiting --> Suspended Not yet recruiting --> Recruiting
- T-Guard (Combination of SPV-T3a-RTA and WT1-RTA) / Xenikos B.V., Jakafi oral (ruxolitinib) / Novartis, Incyte
Results from an Expanded Access Program of Anti-CD3/CD7 Immunotoxin Combination (T-Guard®) for the Treatment of Steroid-Refractory Acute Gvhd (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_6306;
Conclusion Consistent with our recent phase I/II trial, our expanded access program in which 12 patients with high-risk SR-aGVHD received T-guard confirms that this treatment is safe and significantly improves patient outcome. A multicenter phase III study is planned to start in 2019 (BMT-CTN 1802).
- ||| T-Guard (Combination of SPV-T3a-RTA and WT1-RTA) / Xenikos B.V.
Learned lots working with @ProfDFrancis and @mshunshin and these 2 formulae v useful. Helps work out on-the-fly what can be plausibly studied. And more importantly what can't. Doesn't guard against overoptimistic effect sizes - W=2 in this published example.. (Twitter) - Nov 5, 2019
- | T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
New P3 trial: T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) (clinicaltrials.gov) - Oct 16, 2019
P3, N=47, Not yet recruiting, Sponsor: Xenikos
- |||| T-Guard (Combination of SPV-T3a-RTA and WT1-RTA) / Xenikos B.V.
Clinical: Key point on imposter syndrome: Even success doesn’t guard against imposter syndrome- bc of the real fear that you can’t repeat your past success (also falsely attribute to luck) #WIMSummit #WIMStrongertogether I see this all the time in women in academia! (Twitter) - Sep 21, 2019
- || T-Guard (Combination of SPV-T3a-RTA and WT1-RTA) / Xenikos B.V.
Yes, super easy to care for and manage, totally agree. Adaptable to anything. They just aren't guard dogs like a German Shepherd. (Twitter) - Jul 6, 2019
- | T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
Trial completion, Trial primary completion date: Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD (clinicaltrials.gov) - Jun 7, 2017
P1/2, N=20, Completed, Sponsor: Xenikos
A multicenter phase III study is planned to start in 2019 (BMT-CTN 1802). Recruiting --> Completed | Trial primary completion date: Jul 2015 --> Sep 2016
- | T-Guard (SPV-T3a-RTA/WT1-RTA) / Xenikos
New P1/2 trial: Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD (clinicaltrials.gov) - Jan 2, 2014
P1/2, N=20, Recruiting, Sponsor: Xenikos